[["index.html", "Frequentist, Bayesian and hybrid approaches for sample size and power calculations Chapter 1 About 1.1 Usage 1.2 Render book 1.3 Preview book", " Frequentist, Bayesian and hybrid approaches for sample size and power calculations Andr√© Moser, CTU Bern, University of Bern 2023-04-04 Chapter 1 About This is a sample book written in Markdown. You can use anything that Pandoc‚Äôs Markdown supports; for example, a math equation \\(a^2 + b^2 = c^2\\). 1.1 Usage Each bookdown chapter is an .Rmd file, and each .Rmd file can contain one (and only one) chapter. A chapter must start with a first-level heading: # A good chapter, and can contain one (and only one) first-level heading. Use second-level and higher headings within chapters like: ## A short section or ### An even shorter section. The index.Rmd file is required, and is also your first book chapter. It will be the homepage when you render the book. 1.2 Render book You can render the HTML version of this example book without changing anything: Find the Build pane in the RStudio IDE, and Click on Build Book, then select your output format, or select ‚ÄúAll formats‚Äù if you‚Äôd like to use multiple formats from the same book source files. Or build the book from the R console: bookdown::render_book() To render this example to PDF as a bookdown::pdf_book, you‚Äôll need to install XeLaTeX. You are recommended to install TinyTeX (which includes XeLaTeX): https://yihui.org/tinytex/. 1.3 Preview book As you work, you may start a local server to live preview this HTML book. This preview will update as you edit the book when you save individual .Rmd files. You can start the server in a work session by using the RStudio add-in ‚ÄúPreview book‚Äù, or from the R console: bookdown::serve_book() "],["non-inferiority-setting.html", "Chapter 2 Non-inferiority setting 2.1 Aim 2.2 A timeline of selected literature 2.3 Clinical trial setting 2.4 Clinical trial setting 2.5 Frequentist sample size 2.6 Frequentist sample size 2.7 Frequentist sample size 2.8 Frequentist sample size 2.9 Frequentist sample size 2.10 Hybrid approach 2.11 Hybrid approach 2.12 Hybrid approach 2.13 Hybrid approach 2.14 Implications 2.15 Implications 2.16 Implications 2.17 Decomposition of AP 2.18 Decomposition of AP 2.19 Expected power 2.20 To make things more powerful confusing 2.21 EP, PAP, AP 2.22 Conditional Bayesian power 2.23 Conditional Bayesian power 2.24 Average Bayesian power 2.25 Power vocabulary summary (üí™) 2.26 From the SAFE-SSPE study protocol", " Chapter 2 Non-inferiority setting 2.1 Aim Overview ‚Äòpower‚Äô terminology Focus on ‚Äòhybrid‚Äô approach (95%), 5% proper Bayesian Use of SAFE-SSPE trial as example Definition ‚Äòhybrid‚Äô (Spiegelhalter 2004, Section 6.5.2) ‚Äò[‚Ä¶] we have a prior distribution to use in our study design, but that the conclusions of the study will be entirely classical and will not make use of the prior [‚Ä¶]‚Äô 2.2 A timeline of selected literature Book of Spiegelhalter (2004): Bayesian Approaches to Clinical Trials and Health Care Evaluation O‚ÄôHagan (2005): Assurance in Clincial Trials Rufibach et al (2016): Bayesian predictive power: choice of prior [‚Ä¶] Kunzmann et al.¬†(2021): A review of Bayesian Perspectives on Sample Size Derivations from Confirmatory Trials Book of Grieve (2022): Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials 2.3 Clinical trial setting Non-inferiority trial with \\(H_0: \\delta &gt; \\delta^*\\) and \\(H_a: \\delta \\leq \\delta^*\\), where \\(\\delta^*&gt;0\\) non-inferiority margin and treatment effect \\(\\delta=\\mu_1-\\mu_0\\) with \\(Y_{i,1}, \\dots, Y_{i,n} \\sim^{iid} N\\left(\\mu_i, \\sigma^2\\right)\\), \\(i\\in {0,1}\\), \\(\\sigma_i^2\\) known, \\(N=2n\\) SAFE-SSPE: Clinical surveillance (\\(Y_{1}\\)) vs anticoagulant treatment (\\(Y_{0}\\)). Primary outcome is difference in proportions (\\(p_1-p_0\\)) of patients with recurrent venous thromboembolism (VTE). \\(H_0:\\) Clinical surveillance is inferior to anticoagulant treatment, \\(H_a:\\) clinical surveillance is non-inferior. 2.4 Clinical trial setting 2.5 Frequentist sample size \\(H_0: \\delta&gt;\\delta^*\\) vs \\(H_A: \\delta\\leq\\delta^*\\) Let \\(D=\\overline{Y}_{1}-\\overline{Y}_{0}\\) then \\(D \\sim N\\left(\\delta, \\frac{\\tilde\\sigma^2}{n}\\right)\\), where \\(\\tilde\\sigma^2=\\sigma_1^2+\\sigma_1^2\\) Let \\(Z=\\sqrt{n}(D-\\delta)/\\tilde\\sigma \\sim N(\\sqrt{n}(\\hat\\delta-\\delta)/\\tilde\\sigma, 1) \\rightarrow^{asym} N(0,1)\\). ‚ÄòPower‚Äô (conditional!): \\(P(S^{F}|\\delta)=P_{\\delta}(Z\\leq - z_{1-\\alpha})= \\Phi\\left(-z_{1-\\alpha}-\\frac{\\sqrt{n}}{\\tilde\\sigma}(\\delta-\\delta^*)\\right)\\) Sample size: \\(n=(z_{1-\\beta}+z_{1-\\alpha})^2\\frac{\\tilde\\sigma^2}{(\\delta-\\delta^*)^2}\\) (one arm), here \\(\\sigma_i^2=p_i(1-p_i)\\), \\(i\\in {0,1}\\). 2.6 Frequentist sample size Assumptions for sample size calculation specified in study protocol: \\(p_1=0.01\\), \\(p_0=0.01\\), \\(\\delta^*=0.035\\), \\(1-\\beta=0.8\\), \\(\\alpha=0.05\\) library(epiR) alpha &lt;- 0.05 beta &lt;- 0.2 p_0 &lt;- 0.01 p_1 &lt;- 0.01 delta &lt;- p_1-p_0 delta_star &lt;- 0.035 sd_formula &lt;- sqrt(p_0*(1-p_0)+p_1*(1-p_1)) epi.ssninfb(treat=p_1, control=p_0, delta=delta_star, power=1-beta, alpha=alpha, n=NA)$n.total ## [1] 200 n &lt;- 2*((qnorm(1-beta)+qnorm(1-alpha))^2)*((sd_formula^2)/(delta-delta_star)^2) n ## [1] 199.8606 2.7 Frequentist sample size Choice of \\(\\delta_A\\) and \\(\\delta^*\\) in a frequentist setting assumed as fixed At the same time of high importance, because all trial conclusions are based on the (point estimate) choices 2.8 Frequentist sample size What about uncertainty in those choices? From the study protocol: ‚ÄòWe believe that our non-inferiority margin is acceptable to most physicians and patients for the following reasons. First, our margin is within the range of the 3-month VTE recurrence proportion (0.5-5%) below which thrombosis specialists would not initiate anticoagulation for PE.‚Äô Very reasonable that \\(0.005\\leq\\delta^*&lt;0.05\\) Very reasonable that \\(\\delta=0\\) is not ‚Äòtrue‚Äô, but has uncertainty 2.9 Frequentist sample size Choice of \\(\\delta_A\\) and \\(\\delta^*\\) in a frequentist setting assumed as fixed At the same time of high importance, because all trial conclusions are based on the (point estimate) choices 2.10 Hybrid approach Suppose \\(\\delta\\) is a realization from a random variable \\(\\Delta\\) with Gaussian prior \\(\\Delta \\sim N\\left(d, \\frac{\\tilde\\sigma^2}{n_0}\\right)\\). Prior is defined before data collection (‚Äòdesign prior‚Äô). Enthusiastic prior (favors non-inferiority): \\(d=0\\), \\(n_0=6.6\\), \\(P(\\Delta&gt;\\delta^*)=0.05\\). Skeptical prior (favors inferiority): \\(d=\\delta^*\\), \\(n_0=6.6\\), \\(P(\\Delta&gt;0)=0.05\\). Informative prior (clinical expert knowledge): \\(d=0\\), with \\(n_0=25\\). Noninformative prior (please do not use in practice!): \\(d=0\\), with \\(n_0=0.5\\). 2.11 Hybrid approach 2.12 Hybrid approach ‚ÄòPower‚Äô: \\(P(S_{1-\\alpha}|\\delta, \\delta^*)=\\Phi\\left(-z_{1-\\alpha}-\\sqrt{\\frac{n}{\\tilde\\sigma^2}}(\\delta-\\delta^*)\\right)\\) ‚ÄòAverage power‚Äô (Grieve), assurance (O‚ÄôHagan), probability of success (!) (Kunzmann et al., Spiegelhalter): \\(AP=\\int_{\\Delta} P(S^{F}|\\delta, \\delta^*)p(\\delta)d\\delta\\), where \\(\\Delta \\sim p(\\delta)\\) \\(AP=\\Phi\\left(\\sqrt{\\frac{n_0}{n_0+n}}\\left[-z_{1-\\alpha}-\\sqrt{\\frac{n}{\\tilde\\sigma^2}}(d-\\delta^*)\\right]\\right)\\) Upper bound of AP: \\(AP \\rightarrow \\Phi\\left(-(d-\\delta^*)\\sqrt{\\frac{n_0}{\\tilde\\sigma^2}}\\right)\\), as \\({n \\rightarrow \\infty}\\) As \\(n_0 \\rightarrow \\infty\\): \\(AP \\rightarrow P(S_{1-\\alpha}|d)\\) (aka classical power at \\(d\\)) 2.13 Hybrid approach Results: ## type n_0 n AP upper_AP ## 1 Enthusiastic 6.6 100 0.58 0.74 ## 2 Informative 25.0 100 0.65 0.89 ## 3 Noninformative 0.5 100 0.52 0.57 ## 4 Skeptical 6.6 100 0.34 0.50 Question: Is 58% (AP) low compared to 80% (classical ‚Äòpower‚Äô)? Results easily can include inclusion of uncertainty about \\(\\delta^*\\), say, \\(\\delta^*\\sim Un(0.005, 0.05)\\). 2.14 Implications Rufibach et al.¬†(2016) give a closed a formula for the distribution of \\(RPR:=P_{\\Delta}(Z\\leq - z_{1-\\alpha})\\), where \\(\\Delta \\sim N(d,\\tilde\\sigma^2/n_0)\\), and discuss the shape under different prior choices (RPR=‚ÄôRandom probability to reject`, see Kunzmann et al.) u-shaped if \\(n_0&lt;n\\) (‚Äòprior sample‚Äô size is smaller than planned sample size) ## Warning: Removed 128 rows containing missing values (`geom_line()`). 2.15 Implications unimodal if \\(n=n_0\\) ‚Äòhill‚Äô-shape if \\(n_0&gt;n\\) (rather unrealistic interpretation) ## Warning: Removed 9 rows containing missing values (`geom_line()`). 2.16 Implications Allows statements as, for example, \\(P(RPR&gt; 80\\%)\\): 2.17 Decomposition of AP AP integrates over whole \\(\\delta\\) range, including ‚Äònon-favorable‚Äô \\[ AP=\\overbrace{P(Z\\leq - z_{1-\\alpha}, \\Delta&gt;\\delta^*)}^{(1)}+\\overbrace{P(Z\\leq - z_{1-\\alpha}, 0&lt;\\Delta\\leq\\delta^*)}^{(2)} \\\\ +\\overbrace{P(Z\\leq - z_{1-\\alpha}, \\Delta\\leq0)}^{(3)} \\] AP=(1) Probability of Type-I error + (2) ‚ÄòNon-inferior, but treatment effect not relevant‚Äô + (3) ‚ÄòNon-inferior, treatment effect relevant‚Äô \\(AP \\approx P(Z\\leq - z_{1-\\alpha}, \\Delta\\leq0)\\) (see Spiegelhalter), pharma (favors AP, shortterm) vs regulators (favors the other, longterm), see discussion in Kunzmann et al. 2.18 Decomposition of AP Under enthusiastic prior: ## region prop ## 1 &#39;Not significant&#39; 0.41627 ## 2 (3) 0.49073 ## 3 (2) 0.09161 ## 4 (1) 0.00139 2.19 Expected power \\[ AP=\\overbrace{P(Z\\leq - z_{1-\\alpha}, \\Delta&gt;\\delta^*)}^{(1)}+\\overbrace{P(Z\\leq - z_{1-\\alpha}, 0&lt;\\Delta\\leq\\delta^*)}^{(2)} \\\\ +\\overbrace{P(Z\\leq - z_{1-\\alpha}, \\Delta\\leq0)}^{(3)} \\] For our noninferiority setting consider (2)+(3). \\[ P(Z\\leq - z_{1-\\alpha}, \\Delta\\leq\\delta^*)=P(Z\\leq - z_{1-\\alpha}|\\Delta\\leq\\delta^*)P(\\Delta\\leq\\delta^*)\\\\=\\underbrace{E\\left[P_{\\Delta\\leq\\delta^*}(Z\\leq - z_{1-\\alpha})\\right]}_{EP}P(\\Delta\\leq\\delta^*), \\] where \\(EP\\) is ‚Äòexpected power‚Äô (Kunzmann et al.). 2.20 To make things more powerful confusing Spiegelhalter calls \\(P(Z\\leq - z_{1-\\alpha}, \\Delta\\leq\\delta^*)\\) the ‚Äòprior adjusted power‚Äô (PAP): \\[ \\underbrace{P(Z\\leq - z_{1-\\alpha}, \\Delta\\leq\\delta^*)}_{PAP}=\\underbrace{E\\left[P_{\\Delta\\leq\\delta^*}(Z\\leq - z_{1-\\alpha})\\right]}_{EP}\\underbrace{P(\\Delta\\leq\\delta^*)}_{constant} \\] 2.21 EP, PAP, AP Noninferiority setting \\(\\Delta\\leq\\delta^*\\): ## ep pap ap const type ## 1 0.6797 0.3398 0.3418 0.5000 Skeptical ## 2 0.7861 0.5806 0.5828 0.7386 Enthusiastic ## 3 0.7226 0.6454 0.6470 0.8932 Informative ## 4 0.9186 0.5234 0.5233 0.5698 Noninformative 2.22 Conditional Bayesian power Uses posterior distribution to define ‚ÄòBayesian significance‚Äô: \\(S^B:=P(\\Delta\\leq\\delta^*|data)=1-\\epsilon\\), (not \\(\\alpha\\)) Remember \\(D=\\overline{Y}_{1}-\\overline{Y}_{0}\\) with \\(D \\sim N(\\delta, \\frac{\\tilde\\sigma^2}{n})\\), where \\(\\tilde\\sigma^2=\\sigma_1^2+\\sigma_1^2\\) Suppose (again) \\(\\Delta \\sim N(d, \\tilde\\sigma^2/n_0)\\) then the posterior distribution is \\(\\Delta|D \\sim N\\left(\\frac{n_0d+nD}{n_0+n}, \\frac{\\tilde\\sigma^2}{n_0+n}\\right)\\) \\(P(S^B|\\delta)=\\Phi\\left(-\\sqrt{\\frac{n_0+n}{n}}z_{1-\\epsilon}-\\frac{\\sqrt{n}}{\\tilde\\sigma}\\left[\\delta-\\frac{n_0+n}{n}\\delta^*+\\frac{n_0}{n}d\\right]\\right)\\) \\(P(S^{F}|\\delta)=\\Phi\\left(-z_{1-\\alpha}-\\frac{\\sqrt{n}}{\\tilde\\sigma}(\\delta-\\delta^*)\\right)\\) 2.23 Conditional Bayesian power ## delta y type ## 1 0.000 0.83 Bayes: Enthusiastic ## 2 0.035 0.06 Bayes: Enthusiastic ## 3 0.000 0.78 Bayes: Skeptical ## 4 0.035 0.04 Bayes: Skeptical ## 5 0.000 0.80 Frequentist ## 6 0.035 0.05 Frequentist 2.24 Average Bayesian power \\(P(S^B)=\\Phi\\left(-\\sqrt{\\frac{n_0}{n}}z_{1-\\epsilon}-\\frac{\\sqrt{n_0}\\sqrt{n_0+n}(d-\\delta^*)}{\\sqrt{n}\\tilde\\sigma }\\right)\\) ## type AP AP_bayes ## 1 Enthusiastic 0.583 0.594 ## 2 Skeptical 0.341 0.336 ## 3 Informative 0.647 0.715 ## 4 Noninformative 0.524 0.524 Of course, Bayesian average power can again be decomposed into EP and PAP. 2.25 Power vocabulary summary (üí™) ‚ÄòPower‚Äô: Classical power which is conditional on a fixed alternative point estimate. Probability to reject. Bayesian power: Using posterior distribution. Conditional power: Frequentist power in interim analysis (not discussed here). Average power: Marginal probability of rejection, classical power ‚Äòaveraged‚Äô over (design) prior. Assurance. Bayesian predictive power. Expected power: Weighted average of the probability to reject in a ‚Äòrelevant‚Äô region. Also called conditional expected power (üòï). Probability of success (PoS): Very often authors use PoS for ‚Äòaverage power‚Äô. Depends on success definition. 2.26 From the SAFE-SSPE study protocol For sample size calulcation: We used a Monte-Carlo simulation approach based on an Agresti-Caffo confidence interval for risk difference because normal approximation formulas do not hold in case of rare events "],["references.html", "References", " References "],["404.html", "Page not found", " Page not found The page you requested cannot be found (perhaps it was moved or renamed). You may want to try searching to find the page's new location, or use the table of contents to find the page you are looking for. "]]
